t(8;9)(p22;p24)/PCM1-JAK2 Activates SOCS2 and SOCS3 via STAT5

Combined Analysis of Genome-wide Association Studies for Crohn Disease and Psoriasis Identifies Seven Shared Susceptibility Loci

(2012) David Ellinghaus et al.   AMERICAN JOURNAL OF HUMAN GENETICS

Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/PCM1-JAK2-positive chronic eosinophilic leukemia

(2012) E. Lierman et al.   BLOOD

JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths

(2012) A. Tefferi   BLOOD

Janus kinase Inhibition and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure?

(2012) Claire Harrison et al.   BRITISH JOURNAL OF HAEMATOLOGY

The role of cytokine signaling in the pathogenesis of cutaneous T-cell lymphoma

(2012) Ronnie M. Abraham et al.   CANCER BIOLOGY & THERAPY

Janus Kinase Deregulation in Leukemia and Lymphoma

(2012) Edwin Chen et al.   IMMUNITY

Suppression of Cytokine Signaling by SOCS3: Characterization of the Mode of Inhibition and the Basis of Its Specificity

(2012) Jeffrey J. Babon et al.   IMMUNITY

Chronic eosinophilic leukemia with erythroblastic proliferation and the rare translocation t(8;9)(p22;p24) withPCM1–JAK2fusion gene: a distinct clinical, pathological and genetic entity with potential treatment target?

(2012) Monika Prochorec-Sobieszek et al.   LEUKEMIA & LYMPHOMA

The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors

(2011) E. A. Nelson et al.   BLOOD

Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis

(2011) Animesh Pardanani et al.   JOURNAL OF CLINICAL ONCOLOGY

SOCS2 regulates T helper type 2 differentiation and the generation of type 2 allergic responses

(2011) Camille A. Knosp et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Malignant Cutaneous T-Cell Lymphoma Cells Express IL-17 Utilizing the Jak3/Stat3 Signaling Pathway

(2011) Thorbjørn Krejsgaard et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Preclinical Evaluation of Local JAK1 and JAK2 Inhibition in Cutaneous Inflammation

(2011) Jordan S. Fridman et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Centrosomal targeting of tyrosine kinase activity does not enhance oncogenicity in chronic myeloproliferative disorders

(2011) T Bochtler et al.   LEUKEMIA

JAK2 V617F-Dependent Upregulation of PU.1 Expression in the Peripheral Blood of Myeloproliferative Neoplasm Patients

(2011) Tamotsu Irino et al.   PLoS One

PCM1–JAK2-fusion: a potential treatment target in myelodysplastic–myeloproliferative and other hemato-lymphoid neoplasms

(2010) Sylvia Hoeller et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

From the cradle to the grave: activities of GATA-3 throughout T-cell development and differentiation

(2010) Tomonori Hosoya et al.   IMMUNOLOGICAL REVIEWS

JAK2 phosphorylates histone H3Y41 and excludes HP1α from chromatin

(2009) Mark A. Dawson et al.   NATURE

Human Leukemia and Lymphoma Cell Lines as Models and Resources

(2008) Roderick MacLeod et al.   CURRENT MEDICINAL CHEMISTRY

The many faces of the SOCS box

(2008) Julie Piessevaux et al.   CYTOKINE & GROWTH FACTOR REVIEWS

SOCS2: inhibitor of JAK2V617F-mediated signal transduction

(2008) H Quentmeier et al.   LEUKEMIA

SOCS regulation of the JAK/STAT signalling pathway

(2008) Ben A. Croker et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY